Catalytic aerobic oxidation of nor-binaltorphimine (nor-BNI) analogs without 4,5-epoxy bridge affords a more selective ligand for κ opioid receptor than the representative κ antagonist nor-BNI

Chemical and Pharmaceutical Bulletin

Volumn 55, Issue 10, 2007, Pages 1489-1493

  Osa, Yumiko ^a   Ida, Yoshihiro ^a   Fujii, Hideaki ^a   Nemoto, Toru ^a   Hasebe, Ko ^b   Momen, Shinobu ^b   Mochizuki, Hidenori ^b   Nagase, Hiroshi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b TORAY INDUSTRIES INC   (Japan)

Author keywords

receptor; Aerobic oxidation; Morphinan; Opioid; Platinum catalyst

Indexed keywords

6,6',7,7' TETRAHYDRO 6,6' IMINO 14 BETA, 14' ALPHA DIHYDROXY 3,3' DIMETHOXY 7,7' BIMORPHINAN; BINALTORPHIMINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINAN DERIVATIVE; OXYGEN; PLATINUM; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CATALYSIS; OXIDATION;

AEROBIOSIS; CATALYSIS; EPOXY COMPOUNDS; LIGANDS; METHYLATION; MODELS, CHEMICAL; NALTREXONE; NARCOTIC ANTAGONISTS; OXIDATION-REDUCTION; OXYGEN; PLATINUM; RECEPTORS, OPIOID, KAPPA;

EID: 35648994814     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.55.1489     Document Type: Article

References (40)

1. Fowler C. J., Fraser G. L., Neurochem. Int., 24, 401-426 (1994).
2. Pasternak G. W., Wood P. J., Life Sci., 38, 1889-1896 (1986).
3. Tive L. A., Pick C. G., Paul D., Roques B. P., Gacel G. A., Pasternak G. W., Eur. J. Pharmacol., 216, 249-255 (1992).
4. Sofuoglu M., Portoghese P. S., Takemori A. E., J. Pharmacol. Exp. Ther., 257, 676-680 (1991).
5. Jiang Q., Takemori A. E., Sultana M., Portoghese P. S., Bowen W. D., Mosberg H. I., Porreca F., J. Pharmacol. Exp. Ther., 257, 1069-1075 (1991).
6. Fang L., Knapp R. J., Horvath R., Matsunaga T. O., Haaseth R. C., Hruby V. J., Porreca F., Yamamura H. I., J. Pharmacol. Exp. Ther., 268, 836-846 (1994).
7. Clark J. A., Liu L., Price M., Hersh B., Edelson M., Pasternak G. W., J. Pharmacol. Exp. Ther., 251, 461-468 (1989).
8. Horan P., De Costa B. R., Rice K. C., Porreca F., J. Pharmacol. Exp. Ther., 257, 1154-1161 (1991).
9. Gutstein H. B., Akil H., "Goodman and Gilman's The Pharmacological Basis of Therapeutics," 11th ed., ed. by Brunton L. L., Lazo J. S., Parker K. L., McGraw-Hill, New York, 2005, pp. 547-606.
10. Dhawan B. N., Cesselin F., Raghubir R., Reisine T., Bradley P. B., Portoghese P. S., Hamon M., Pharmacol. Rev., 48, 567-592 (1996).
11. Tseng L. F., Narita M., Mizoguchi H., Kawai K., Mizusuna A., Kamei J., Suzuki T., Nagase H., J. Pharmacol. Exp. Ther., 280, 600-605 (1997).
12. Portoghese P. S., Sultana M., Nagase H., Takemori A. E., Eur. J. Pharmacol., 218, 195-196 (1992).
13. Nock B., "The Pharmacology of Opioid Peptides," ed. by Tseng L. F., Harwood Academic Publishers, Singapore, 1995, pp. 29-56.
14. Teberi M., Magnan J., Eur. J. Pharmacol., Mol. Pharmacol., 188, 379-389 (1990).
15. Millan M. J., Trends Pharmacol. Sci., 11, 70-76 (1990).
16. Mucha R. F., Herz A., Psychopharmacology, 86, 274-280 (1985).
17. Funada M., Suzuki T., Narita M., Misawa M., Nagase H., Neuropharmacology, 32, 1315-1323 (1993).
18. Shippenberg T. S., Herz A., NIDA Res. Monogr., 75, 563-566 (1986).
19. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., Tajima C., Endo T., Chem. Pharm. Bull., 46, 366-369 (1998).
20. Tsuji M., Takeda H., Matsumiya T., Nagase H., Narita M., Suzuki T., Life Sci., 68, 1717-1725 (2001).
21. Endoh T., Matsuura H., Tajima A., Izumimoto N., Tajima C., Suzuki T., Saitoh A., Suzuki T., Narita M., Tseng L. F., Nagase H., Life Sci., 65, 1685-1694 (1999).
22. Endoh T., Tajima A., Kamei J., Suzuki T., Narita M., Tseng L. F., Nagase H., Eur. J. Pharmacol., 387, 133-140 (2000).
23. Tsuji M., Yamazaki M., Takeda H., Matsumiya T., Nagase H., Tseng L. F., Narita M., Suzuki T., Eur. J. Pharmacol., 394, 91-95 (2000).
24. Mori T., Takeda H., Matsumiya T., Nagase H., Yamazaki M., Narita M., Suzuki T., Life Sci., 66, PL353-358 (2000).
25. Endoh T., Tajima A., Izumimoto N., Suzuki T., Saitoh A., Suzuki T., Narita M., Kamei J., Tseng L. F., Mizoguchi H., Nagase H., Jpn. J. Pharmacol., 85, 282-290 (2001).
26. Mori T., Nomura M., Yoshizawa K., Nagase H., Narita M., Suzuki T., Life Sci., 75, 2473-2482 (2004).
27. Portoghese P. S., Nagase H., Lipkowsky A. W., Larson D. L., Takemori A. E., J. Med. Chem., 31, 836-841 (1988).
28. Nock B., Giordano A. L., Cicero T. J., O'Connor L. H., J. Pharmacol. Exp. Ther., 254, 412-419 (1990).
29. Lipkowsky A. W., Nagase H., Portoghese P. S., Tetrahedron Lett., 27, 4257-4260 (1986).
30. Schmidhammer H., Smith C. F. C., Hev. Chim. Acta, 72, 675-677 (1989).
31. Schmidhammer H., Ganglbauer E., Mitterdorfer J., Rollinger J. M., Smith C. F. C., Hev. Chim. Acta, 73, 1779-1783 (1990).
32. Casy A. F., Parfitt R. T., "Opioid Analgesics: Chemistry and Receptors," Plenum Press, New York, 1986, pp. 105-151.
33. Guise G. B., Ritchie E., Taylor W. C., Aust. J. Chem., 18, 1279-1286 (1965).
34. Witkop B., Patrick J. B., Rosenblum M., J. Am. Chem. Soc., 73, 2641-2647 (1951).
35. Leete E., J. Am. Chem. Soc., 83, 3645-3647 (1961).
36. Sundberg R. J., "The Chemistry of Indoles," Academic Press, New York, 1970, pp. 282-315.
37. A radical process might also be taken into account. Two molecules of hydroperoxy radicals corresponding to hydroperoxide 14 could produce ketone, alcohol, and oxygen via an unstable tetraoxide. (Chemical Equation Presented) Lowry T. H., Richardson K. S., "Mechanism and Theory in Organic Chemistry," 3rd ed., Harper & Row, Publishers, New York, 1987, pp. 779-782.
38. Gossauer A., Nesvadba P., "Pyrroles: Part One: The Synthesis and the Physical and Chemical Aspects of the Pyrrole Ring," ed. by Jones R. A., John Wiley and Sons, Canada, 1990, pp. 499-536.
39. Casy A. F., Parfitt R. T., "Opioid Analgesics: Chemistry and Receptors," Plenum Press, New York, 1986, pp. 9-104.
40. Cheng Y., Prusoff W. H., Biochem. Pharmacol., 22, 3099-3108 (1973).